Stock events for Immunovant, Inc. (IMVT)
Immunovant's stock has rallied, increasing 68.7% over the past six months and 40% over the past year. In December 2025, the company announced a $550 million underwritten public offering of common stock, with Roivant Sciences participating, expected to extend the cash runway through the potential commercial launch of IMVT-1402 for Graves' Disease. Q3 2025 results reported a narrower-than-expected quarterly loss of -$0.61 per share in February 2026, leading analysts to raise price targets. The stock hit a new 52-week high of $29.25 in February 2026, and insider selling was reported in December 2025.
Demand Seasonality affecting Immunovant, Inc.’s stock price
As a clinical-stage biopharmaceutical company without commercialized products, Immunovant, Inc. does not experience traditional demand seasonality. The company's focus is on research, development, and clinical trials, with demand primarily driven by investor interest in pipeline progress and future commercial potential.
Overview of Immunovant, Inc.’s business
Immunovant, Inc. is a clinical-stage immunology company focused on developing therapies for autoimmune diseases, operating in the Biotechnology industry. Its pipeline includes batoclimab and IMVT-1402, targeting the neonatal fragment crystallizable receptor (FcRn) to reduce immunoglobulin G (IgG) antibodies. Batoclimab is being developed for conditions like myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves' disease. IMVT-1402 is in development for autoimmune diseases, including Graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus and Sjögren's disease.
IMVT’s Geographic footprint
Immunovant, Inc. is headquartered in New York, New York, and has an office in Durham, North Carolina.
IMVT Corporate Image Assessment
Immunovant's brand reputation has been largely positive due to pipeline progress and a strong financial position, improving investor confidence. The company has a consensus "Moderate Buy" rating from analysts, with an average price target suggesting potential upside, driven by positive developments in clinical programs for batoclimab and IMVT-1402. However, there have been "SHAREHOLDER ALERT" announcements by Purcell & Lefkowitz LLP in February and January 2026, indicating shareholder investigations.
Ownership
Immunovant, Inc. has significant institutional ownership, with 252 institutional owners and shareholders holding 104,555,782 shares as of March 5, 2026. Major institutional shareholders include Fmr Llc, Deep Track Capital, LP, Vanguard Group Inc, BlackRock, Inc., Armistice Capital, Llc, Baker Bros. Advisors Lp, Morgan Stanley, State Street Corp, Rtw Investments, Lp, and Two Seas Capital LP. Roivant Sciences Ltd. is the largest individual shareholder, owning 113,317,007 shares, representing 55.68% of the company. Institutional shareholders collectively hold 53.36% of Immunovant stock, while insiders own 58.29%.
